Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance

Medpace Holdings IncTrade
Tencent Music Entertainment Group - ADRTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Tencent Music Entertainment Group - ADR trades at $8.46 (market cap $16.09B). The key difference: Medpace Holdings Inc and Tencent Music Entertainment Group - ADR are close in size by market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

MEDPTME
Market Cap
$16.90B$16.09B
Sector
TechnologyMedia
52-Week High
$620.59$26.36
52-Week Low
$393.42$8.16
Enterprise Value
$16.52B$14.05B
Dividend Yield
2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Tencent Music Entertainment Group - ADR

TME stock trades at $8.45, down 14.65% in the last session amid mixed earnings results. The company reported Q2 2026 revenue growth of 6% year-over-year but faces slowing operational growth and competitive pressures. Valuation metrics appear reasonable with a P/E of 10.29 and P/S of 2.71, while profitability remains strong with a net income margin of 26.28%. Technical indicators signal a bearish trend, with the stock near key support levels.

The outlook is cautious; while TME's fundamentals are solid with robust cash flow and profitability, near-term headwinds from competition and market sentiment pose risks. Analyst consensus is divided, with 46% buy ratings but 50% hold, reflecting uncertainty over growth sustainability. Investors should weigh the attractive valuation against execution risks in a challenging environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Tencent Music Entertainment Group - ADR

TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.

Read more on TME